The risk reduction of HHF was consistent in groups of HF (RR 0.72, 95% CI 0.64–0.80, I2 = 8%) and non-HF (RR 0.74, 95% CI 0.61–0.89, I2 = 0), but the effect of the low SGLT2/SGLT1 selectivity inhibitor was insignificant in non-HF patients. Here, SLC5A2 is linked to hydrops fetalis.